Kala Pharmaceuticals is a biopharmaceutical company that specializes in developing and commercializing therapies for eye diseases using proprietary mucus-penetrating particles technology. They offer several product candidates under development for different applications, including persistent corneal epithelial defects and short-term treatment of the signs and symptoms of dry eye disease. Additionally, their preclinical development products focus on retinal diseases and selective glucocorticoid receptor modulators.